Endocrine News Podcast

The endocrine workforce shortage is affecting the lives of endocrinologists and the patients they treat. Many practices would benefit from any support that would give endocrinologists more capacity to focus where they really need to. Could advance practice providers, such as nurse practitioners and physicians assistants, be able to provide that support if they had a little more training?   The Endocrine Society and the American Association of Nurse Practitioners? (AANP) think so. Together they have developed a new program called Clinical Advantage: Endocrinology Certificate for Advanced Practice Providers. What does the certificate represent, how does the program work?   To help answer those questions and more host Aaron Lohr talks with two guests who helped develop the program: Sara R. MacLeod, DO, MPH, Assistant Professor of Medicine at University of Rochester; and Shannon K. Idzik, DNP, CRNP, ANP-BC, FAANP, FAAN, Professor and Associate Dean for the Doctor of Nursing Practice Program at University of Maryland School of Nursing.   Listen to learn how Clinical Advantage is working to address the shortage. Show notes are available at

For some people, diabetes can be very hard to control, even with the standard glucose-lowering therapies. Several studies have demonstrated that endogenous hypercortisolism is prevalent among these individuals. What’s the relationship between type 2 diabetes and hypercortisolism, and what do health care providers need to know about that relationship? To help answer those questions, host Aaron Lohr talks with two guests., is a professor of medicine, assistant dean for clinical research, the Tullis-Tulane Alumni Chair in Diabetes, and chief of the section of endocrinology at Tulane University Medical Center in New Orleans., is a professor of medicine and surgery at the Medical College of Wisconsin. Drs. Fonseca and Findling are authors of an article published in the journallooking at the CATALYST study: “Inadequately Controlled Type 2 Diabetes and Hypercortisolism: Improved Glycemia With Mifepristone Treatment.” This episode is made possible by support from Corcept Therapeutics Inc. Show notes are available at— for helpful links or to hear more podcast episodes, visit

In recent years, we have seen tremendous growth not just in the popularity of anti-obesity medications, but also in the medications themselves, how effective they are, how many there are. What exactly has changed during this rapid evolution? How safe and effective are these medications today? What challenges still exist in using them? To help answer these questions, host Aaron Lohr speaks with, professor of medicine, medical director of Vanderbilt Obesity Medicine, and founding program director of the Obesity Medicine Fellowship at Vanderbilt University Medical Center. Dr. Srivastava presented at the Endocrine Society’s Obesity Fellows Conference in September 2025. The title of her presentation was “Pharmacological Approaches to Treating and Understanding Complicated Obesity.” Listening to this episode can earn you 0.5 ABIM MOC points and 0.5 AMA PRA Category 1 credits. If you are interested in those points and credits,. You can find a link in this episode’s show notes. After that pre-test, listen to this episode, then take the post-test. This episode is made possible by educational grants from Lilly and Novo Nordisk. Show notes are available at— for helpful links or to hear more podcast episodes, visit

In the last five years, the field of artificial intelligence and robotics has taken off and has become a part of our everyday life, and it continues to grow and evolve. How are AI and robotics shaping the field of medicine? How is it improving the lives of doctors and patients? We used to ask, “What is the role of AI in medicine?” Are we getting closer to a time where we’ll be asking what the role is of humans? To help us answer these questions, host Aaron Lohr talks with. Dr. Heshmati has been a physician for 49 years and an endocrinologist for 45 years, with experience in clinical research and academia and in the pharmaceutical biotech industry. He founded Endocrinology Metabolism Consulting, based in Anthem, Ariz., and presented an abstract at ENDO 2025 titled,Show notes are available at— for helpful links or to hear more podcast episodes, visit

Technically known as glucagon-like peptide-1 receptor agonists, or GLP-1, these drugs have been around for years for treating diabetes. Now it seems most people think of GLP-1 drugs as medications to lose weight, and these medications are so popular that for a time, supply could not meet demand, leaving many to seek compounded GLP-1 medications, which were more accessible and affordable. However, compounded medications are not FDA-approved, and there are questions regarding their safety and efficacy. What do doctors and patients need to know when considering using compounded obesity medications? To help answer this, host Aaron Lohr talks with, an endocrinologist at NYU Langone Division of Endocrinology. Dr. Weintraub serves on the exam writing committee for the American Board of Obesity Medicine. Support for this episode was provided by Lilly. Show notes are available at— for helpful links or to hear more podcast episodes, visit

Bariatric surgery is a procedure used to manage obesity and obesity-related conditions. While studies have shown that bariatric surgery leads to significant weight loss, are there cases where it may be important to consider reversing the procedure? What would such cases look like? How effectively can bariatric surgery be reversed? To help explore those questions, host Aaron Lohr talks with, a second-year endocrine fellow at the University of Rochester Medical Center. She and colleagues presented an abstract at ENDO 2025 titled, “Going Backwards as a Means of Moving Forward: Severe Hypoglycemia After Bariatric Surgery.” Show notes are available at— for helpful links or to hear more podcast episodes, visit

In this episode, we take a closer look at tirzepatide, a type 2 diabetes medication also used to help with weight loss. Postmenopause weight gain can be a normal part of aging, and there are some questions about whether medications like tirzepatide could be useful and safe for postmenopausal women. Host Aaron Lohr talks with, assistant professor of medicine at Mayo Clinic Florida, and, a research fellow at Mayo Clinic College of Medicine & Science. They presented an abstract at ENDO 2025 titled, “One-Year Real-World Weight Loss Outcomes with Tirzepatide in Postmenopausal Women With and Without Hormone Therapy.” Show notes are available at— for helpful links or to hear more podcast episodes, visit

In the United States, the Food and Drug Administration doesn’t regulate supplements for safety and efficacy, so manufacturers don’t have to disclose their ingredients. We can’t always know for certain what’s in supplements we buy over the counter. Host Aaron Lohr talks with, an endocrine specialist at Ochsner Lafayette General Medical Center in Louisiana. Dr. Pattipati presented a study at ENDO 2025 in San Francisco titled, “Beware of the Hidden Ingredients and Supplement Use in Your Patients With Elevated Testosterone.” The presentation describes a case where a patient unknowingly ingested an ingredient that had a significant endocrine impact. Show notes are available at— for helpful links or to hear more podcast episodes, visit

Recently the Endocrine Society held its 12th annual Type 1 Diabetes Fellows Series program, which combines comprehensive education on type 1 diabetes with career development opportunities to build knowledge, practical skills, and a lasting network of colleagues. For this episode, host Aaron Lohr talks with, medical director of the Diabetes Institute and director of the Clinical Research Center at the University of Florida. Dr. Schatz gave a talk at the fellows series program titled, “Immunotherapies for Type 1 Diabetes: Need for Early Detection and Screening.” This year’s fellows series program and this episode were made possible by the support of Abbott Diabetes Care, CeQur Corp., Dexcom Inc., Insulet Corp., Breakthrough T1D (formerly the Juvenile Diabetes Research Foundation), Lilly USA, Mankind Pharma Limited, Medtronic Inc., Novo Nordisk Inc., and Vertex Pharmaceuticals Inc. Show notes are available at— for helpful links or to hear more podcast episodes, visit

In this episode, we cover type 1 diabetes and especially insulin delivery systems. Host Aaron Lohr talks with, from Northwestern University’s Feinberg School of Medicine and, director of education and training in diabetes technology at the Cleveland Clinic. This episode is certified for up to 0.5 AMA PRA Category 1 credits and ABIM MOC points. However, claiming those points requires taking a pre-episode test. Then you must listen to the episode on the Endocrine Society’s Center for Learning website, followed by a post-episode test and evaluation. Please check the show notes for the appropriate link. This episode is supported by educational grants by MannKind Corp. and Insulet Corp. Show notes are available at— for helpful links or to hear more podcast episodes, visit

Papillary thyroid cancer is the most common type of thyroid cancer, and yet in rare cases, this cancer may originate in locations other than the thyroid glands. In this episode, host Aaron Lohr talks about causes, prevalence, and treatment for papillary thyroid cancer and the rare phenomenon known as ectopic papillary thyroid cancer with, of University of Texas Health Science Center at Houston. Dr. Dhir and colleagues presented research at ENDO 2025 in San Francisco titled, “Where Is the Primary Papillary Thyroid Cancer?” Show notes are available at— for helpful links or to hear more podcast episodes, visit

After seven years, we have reached our 100th episode! For this, we talk about growth hormone deficiency, about causes, prevalence, why some types may become permanent, available treatments, and the importance of adherence to treatment plans. Host Aaron Lohr talks with, of Bambino Gesù Children’s Hospital in Rome, Italy. Recently, Dr. Loche and colleagues presented research at ENDO 2025 in San Francisco titled, “Adherence to GH Treatment in the Transition Age: A Prospective Study.” Show notes are available at https://www.endocrine.org/podcast/enp100 — for helpful links or to hear more podcast episodes, visit https://www.endocrine.org/podcast

Recently the Endocrine Society’s Bone and Mineral Special Interest Group discussed the importance of fracture liaison services and how they contribute to an improved quality of life for patients and cost saving for the facility. An important part of the discussion revolved around a recent perspective published intitled, “Coordinating Multidisciplinary Care — Improving Outcomes after Fragility Fractures.” The article notes that despite the benefits of fracture liaison services, the lack of reimbursement for those services in the United States is a significant financial barrier, rendering the service underutilized. The article further states that the global burden of hip fractures is expected to double over the next few decades. Are we looking at an impending crisis? What role should fracture liaison services play in reducing treatment gaps and improving post-fracture care? Host Aaron Lohr talks with the three authors of thatperspective:, associate professor of endocrinology and metabolism at Campus Bio-Medico University of Rome, Italy;, professor medicine at Monash University in Melbourne, Vic., Australia; and, professor of medicine at Marcus Institute for Aging Research at Hebrew Senior Life. Show notes are available at https://www.endocrine.org/podcast/enp99 — for helpful links or to hear more podcast episodes, visit https://www.endocrine.org/podcast

Increased prescription of opioid medications like oxycodone and hydrocodone has led to widespread misuse of both prescription and non-prescription opioids. But did you know that opioid misuse can significantly impact the endocrine system? The Endocrine Society recently published a scientific statement titled, “Exogenous Opioids and the Human Endocrine System: An Endocrine Society Scientific Statement.” The statement reviews data on the use and misuse of opioids and discusses recent research on the endocrine-related implications of opioid use. Host Aaron Lohr talks to one of the statement’s authors,, a professor from the Institute of Metabolism and Systems Research at the University of Birmingham in the United Kingdom. Show notes are available at https://www.endocrine.org/podcast/enp98-opioids-and-the-endocrine-system — for helpful links or to hear more podcast episodes, visit https://www.endocrine.org/podcast

What treatment options are available for children and adolescents with obesity? Host Aaron Lohr takes on this topic with, associate professor in the Child Health Evaluation and Research Center at the University of Michigan, and, a clinical fellow at Cincinnati’s Children’s Hospital. Both took part in the Endocrine Society’s recent obesity fellows conference. This episode is supported by an educational grant from Lilly and Novo Nordisk. Also, this episode is available to listen for 0.5 CME credits, but you must follow the link to the show notes and read the instructions in order to earn those points. Show notes are available at https://www.endocrine.org/podcast/enp97-childhood-obesity-treatment — for helpful links or to hear more podcast episodes, visit https://www.endocrine.org/podcast

There is a lot of interest in automated insulin delivery systems, and they were covered in depth at the Endocrine Society’s Type 1 Diabetes Fellows Series, held earlier this year. Joining host Aaron Lohr to talk about these delivery systems is Grazia Aleppo, MD, a professor of medicine at Northwestern University and a presenter at the T1D Fellows Series. Show notes are available at https://www.endocrine.org/podcast/enp96-automated-insulin-delivery-systems — for helpful links or to hear more podcast episodes, visit https://www.endocrine.org/podcast

There are plenty of studies showing that chemicals found in the environment can directly impact human health. Some new research finds that certain environmental compounds may trigger early female puberty. Joining host Aaron Lohr to talk about that research is Natalie Shaw, MD, a Lasker clinical research scholar and principal investigator of the pediatric neuroendocrinology group in the Clinical Research Branch of the National Institute of Environmental Health Sciences. Dr. Shaw and colleagues authored an article recently published in the journal Endocrinology titled, “Identification of Environmental Compounds That May Trigger Early Female Puberty by Activating Human GnRHR and KISS1R.” Show notes are available at https://www.endocrine.org/podcast/enp95-environmental-impact-on-early-female-puberty — for helpful links or to hear more podcast episodes, visit https://www.endocrine.org/podcast

It’s been a few years, but we are here with an update on acromegaly, covering prevalence, diagnosis, traditional treatment, new therapies, and current gaps in understanding. Host Aaron Lohr talks again with Maria Fleseriu, MD, professor of medicine and professor of neurological surgery at Oregon Health & Science University School of Medicine and director of OHSU’s Pituitary Center. Dr. Fleseriu also serves on the Board of Directors of the Endocrine Society. Show notes are available at https://www.endocrine.org/podcast/enp94-update-on-acromegaly — for helpful links or to hear more podcast episodes, visit https://www.endocrine.org/podcast

Host Aaron Lohr talks with Rita Kalyani, MD, professor of medicine at Johns Hopkins University School of Medicine and president-elect of medicine and science at the American Diabetes Association. Earlier this year, Dr. Kalyani and colleagues published a position statement in The Journal of Clinical Endocrinology & Metabolism titled, “Prioritizing Patient Experiences in the Management of Diabetes and Its Complications: An Endocrine Society Position Statement.” Show notes are available at https://www.endocrine.org/podcast/enp93-patience-experience-in-managing-diabetes — for helpful links or to hear more podcast episodes, visit https://www.endocrine.org/podcast

In this episode, we talk about pheochromocytomas. Host Aaron Lohr talks with Nikhitha Chandrashekar, MD, who recently finished her endocrinology fellowship at University Hospitals Case Western Reserve University in Cleveland. Dr. Chandrashekar presented a case study on pheochromocytomas at ENDO 2024. Show notes are available at https://www.endocrine.org/podcast/enp92-pheochromocytomas — for helpful links or to hear more podcast episodes, visit https://www.endocrine.org/podcast

Our bodies typically do a remarkable job of recovering from certain injuries, and thyroid hormone signaling has an essential role to play there. But what is that process like for someone with hypothyroidism, and is there a unique role in that process for muscle stem cells? Host Aaron Lohr talks with Paola Aguiari, PhD, a senior research specialist at Children’s Hospital Los Angeles. She presented an abstract at ENDO 2024 titled, “Hypothyroidism Impairs Skeletal Muscle Regeneration After Injury.” Show notes are available at https://www.endocrine.org/podcast/enp91-hypothyroidism-and-muscle-regeneration — for helpful links or to hear more podcast episodes, visit https://www.endocrine.org/podcast

We all know that stress leads to a number of negative outcomes. In this episode, we talk about how early life stress may influence youth substance use initiation and some endocrine factors that may be helping to drive that influence. Host Aaron Lohr talks with Alexandra M. Donovan, PhD, of the Charles R. Drew University of Medicine and Science. Dr. Donovan recently presented an abstract at ENDO 2024 titled, “Early Life Stress and Pubertal Predictors of Youth Substance Use Initiation: Does Sex Moderate the Relationship Between Early Life Stress, Puberty, and Substance Use Initiation?” Show notes are available at https://www.endocrine.org/podcast/enp90-early-life-stress-and-substance-use — for helpful links or to hear more podcast episodes, visit https://www.endocrine.org/podcast

In this episode, we talk about brown fat and some new discoveries in how it regulates metabolic function. Joining host Aaron Lohr is Marsel Lino, PhD, a research fellow at Joslin Diabetes Center in Boston. Dr. Lino presented an abstract at ENDO 2024 titled, “A New Layer of Endocrine Regulation: Brown Fat Secretes Exosomal MicroRNAs, Which Regulate Metabolic Functions and Distal Organs.” Show notes are available at https://www.endocrine.org/podcast/enp89-brown-fat-and-metabolic-function — for helpful links or to hear more podcast episodes, visit https://www.endocrine.org/podcast

Many people take over-the-counter supplements for a variety of reasons, but it isn’t always clear what’s in those supplements. And while they may be intended to help, some may cause harm. In this episode, host Aaron Lohr talks with Kevin Wei, MD, from the University of Southern California/Los Angeles General Medical Center Internal Medicine Residency Program about the presence of glucocorticoids in some over-the counter supplements and why that may be a concern. Dr. Wei and colleagues presented an abstract at ENDO 2024 titled, “Characterizing the Physiological Side Effects of Over-the-Counter Arthritis Supplements.” Show notes are available at https://www.endocrine.org/podcast/enp88-glucocorticoids-in-supplements — for helpful links or to hear more podcast episodes, visit https://www.endocrine.org/podcast

For those of us who try to lose weight at some point in time, we know the frustration of losing weight and feeling good about that, only to see that weight return. Why does that happen? Is the process the same for adults and adolescents? Is there any way to mitigate that weight regain? Joining host Aaron Lohr is Eric Bomberg, MD, assistant professor at the Center for Pediatric Obesity Medicine at the University of Minnesota. Dr. Bomberg recently presented an abstract at ENDO 2024 titled, “Hormonal and Physiological Changes Following Short-Term Weight Loss in Adolescents With Obesity and the Role of Glucagon-Like Peptide 1 Receptor Agonist to Counteract Adaptations.” Show notes are available at https://www.endocrine.org/podcast/enp87-short-term-weight-loss-in-adolescents-with-obesity — for helpful links or to hear more podcast episodes, visit https://www.endocrine.org/podcast

This episode focuses on machine learning and how it may help diagnose metabolic dysfunction-associated steatotic liver disease (MASLD). Host Aaron Lohr talks with Christos S. Mantzoros, MD, PhD, professor of medicine at Harvard Medical School and the editor-in-chief of the journal. Dr. Mantzoros and his team presented their work at ENDO 2024 in Boston, and their abstract was title, “Accurate machine-learning-based diagnosis of at-risk MASH and MASLD subtypes using categorical, radiant boosting, and select clinical, biochemical, and metabolomic measurements: Building highly robust models with few variables through a multi-national, multi-center, biopsy-proven cohort.” Show notes are available at https://www.endocrine.org/podcast/enp86-machine-learning-and-steatotic-liver-disease — for helpful links or to hear more podcast episodes, visit https://www.endocrine.org/podcast

In this episode, we focus on the Treat and Reduce Obesity Act legislation and the obesity epidemic. Host Aaron Lohr talks with U.S. Rep. Raul Ruiz, MD, a physician and currently the U.S. Representative for California’s 25th congressional district. Rep. Ruiz received his medical degree from Harvard University and completed his residency in emergency medicine at the University of Pittsburgh and a fellowship in international emergency medicine at Brigham and Women’s Hospital in Massachusetts. He worked as an emergency room doctor at Eisenhower Medical Center in Rancho Mirage, Calif., until he was elected to Congress in 2012. Rep. Ruiz talks about his background, his experience in treating obesity and its comorbidities, and the Treat and Reduce Obesity Act of 2023. Support for this podcast was provided by Eli Lilly & Company. Show notes are available at https://www.endocrine.org/podcast/enp85-treat-and-reduce-obesity-act — for helpful links or to hear more podcast episodes, visit https://www.endocrine.org/podcast

In a special episode, we discuss a complex, rare disease, fibrodysplasia ossificans progressiva, or FOP. Host Aaron Lohr talks with three guests: Eileen M. Shore, PhD, Cali and Weldon Research Professor in FOP and co-director of the Center for Research in FOP and Related Disorders at the University of Pennsylvania School of Medicine; Elisabeth Marelise W. Eekhoff, MD, PhD, endocrinologist, principal investigator, and medical specialist at Amsterdam University Medical Center in the Netherlands; and Michelle Davis, executive director of the International Fibrodysplasia Ossificans Progressiva Association. This episode is certified for 0.5 American Medical Association Physician’s Recognition Award (AMA PRA) Category 1™ credits and 0.5 American Board of Internal Medicine Maintenance of Certification (ABIM MOC) points. If you want those credits and points, you will have to browse to the Endocrine Society’s Center for Learning, take a pre-test, listen to this episode there, then take a post-test. This episode is supported by an educational grant from Ipsen Biopharmaceuticals Inc. Show notes, including link to the Center for Learning, are available at https://www.endocrine.org/podcast/enp84-fibrodysplasia-ossificans-progressiva — for helpful links or to hear more podcast episodes, visit https://www.endocrine.org/podcast

We all know that a sedentary lifestyle is not healthy for anyone, but just how strongly is physical activity connected to lipid levels in childhood? Host Aaron Lohr talks with Andrew Agbaje, MD, PhD, a physician and pediatric clinical epidemiologist at the University of Eastern Finland. He has authored a study recently published in The Journal of Clinical Endocrinology & Metabolism titled, “Associations of Sedentary Time and Physical Activity From Childhood With Lipids: A 13-Year Mediation and Temporal Study.” Show notes are available at https://www.endocrine.org/podcast/enp83-sedentary-time-and-physical-activity-effects-on-childhood-lipid-levels — for helpful links or to hear more podcast episodes, visit https://www.endocrine.org/podcast

In this episode, we learn about endocrine-disrupting chemicals known as perfluoroalkyl and polyfluoroalkyl substances (PFAS), which break down so slowly that they have been called “forever chemicals.” Where can PFAS be found? What exactly is their effect on human health? What are manufacturers doing to limit exposure, and is it enough? Host Aaron Lohr talks with Benson T. Akingbemi, PhD, professor of anatomy and developmental biology at Auburn University. Dr. Akingbemi and colleagues recently published an article on PFAS in the journal Endocrinology titled, “Legacy and Emerging Perfluoroalkyl and Polyfluoroalkyl Substances Regulate Steroidogenesis in the Male Gonad.” Show notes are available at https://www.endocrine.org/podcast/enp82-pfas — for helpful links or to hear more podcast episodes, visit https://www.endocrine.org/podcast

According to the National Institutes of Health, more than two in five adults have obesity in the United States, and nearly one in three is overweight. To equip health care practitioners with the resources they need to treat patients with obesity, the Endocrine Society recently held its innaugual obesity fellows program, an exclusive, application-based, educational activity for current fellows. The program covered a wealth of information, and host Aaron Lohr talks with Amy Rothberg, MD, DABOM, program chair and a clinical professor of internal medicine at the University of Michigan’s School of Public Health. If you weren’t able to attend the fellows program, we have a free series of on-demand lectures available online, and those are accredited. With thanks to Lilly USA LLC and Novo Nordisk for making both the obesity fellows program and this podcast episode possible through an unrestricted, educational grant. Show notes, including a link to the Endocrine Society Learning Center for earning ABIM points and AMA PRA Category 1 credits, are available at https://www.endocrine.org/podcast/enp81-obesity-fellows-program — for helpful links or to hear more podcast episodes, visit https://www.endocrine.org/podcast

We all know that sleep is important, but sometimes we just don’t get enough. We also know the normal side effects from lack of sleep, but are there other, metabolic, and neuronendocrine effects from short sleep that we don’t know about. Host Aaron Lohr talks about this with Iris CM Pelsma, an academic researcher at Leiden University Medical Center in the Netherlands. She and her colleagues presented a study earlier this year, at ENDO 2023, titled, “Metabolic and Neuroendocrine Adaptability Following One Night of Partial Sleep Restriction in Dutch Males.” Show notes are available at https://www.endocrine.org/podcast/enp80-metabolic-and-neuroendocrine-effects-of-short-sleep — for helpful links or to hear more podcast episodes, visit https://www.endocrine.org/podcast

Today’s topic is type 1 diabetes. What are some of the biggest challenges facing us today when it comes to diagnosing and treating type 1 diabetes, and how can we meet those challenges? Host Aaron Lohr talks with Irl Hirsch, MD, from the UW Diabetes Institute at the University of Washington. Dr. Hirsch and Davida Kruger, NP, from Henry Ford Health in Detroit co-chaired the Endocrine Society’s type 1 diabetes fellows series. That program and this podcast episode were both made possible by unrestricted, educational grants from Abbott Diabetes Care Inc., CeQur Corp., Dexcom, Insulet, JDRF, Lilly USA LLC, MannKind Corp., Novo Nordisk, Prevention Bio, Vertex, and Tandem Diabetes Care. Show notes are available at https://www.endocrine.org/podcast/enp79-type-1-diabetes-update — for helpful links or to hear more podcast episodes, visit https://www.endocrine.org/podcast

We know that illicit use of anabolic-androgenic steroids is dangerous, but cessation comes with its own challenges. Today we’re talking about a study presented at ENDO 2023 titled, “Self-Administration of Post-Cycle Therapy Is Associated With Increased Probability of Subsequent Normalisation of Reproductive Hormones Following Anabolic-Androgenic Steroid Cessation in Men.” Joining host Aaron Lohr to talk about it is one of the study authors, Channa Jayasena, MD, PhD, a specialist in reproductive endocrinology and a research team lead at Imperial College London. Show notes are available at https://www.endocrine.org/podcast/enp78-post-cycle-therapy-following-anabolic-androgenic-steroid-cessation — for helpful links or to hear more podcast episodes, visit https://www.endocrine.org/podcast

We look at a study, presented at ENDO 2023, about the endocrine-disrupting chemicals known as phthalates, or plasticizers, and their effects on fetal and neonatal endocrine puberty. Host Aaron Lohr talks with Mary Bunnell from the University of Illinois Urbana-Champaign, co-author of the study, titled, “Prenatal Phthalate Exposure Alters the Pattern of Fetal and Neonatal Endocrine Puberty in a Sex-specific Manner.” Show notes are available at https://www.endocrine.org/podcast/enp77-phthalates-and-endocrine-puberty — for helpful links or to hear more podcast episodes, visit https://www.endocrine.org/podcast

Today we look at a study from ENDO 2023 about COVID-19 exposure and weight gain in infants. Host Aaron Lohr talks with Mollie Ockene, a Clinical Research Coordinator at Massachusetts General Hospital and a co-author of the study, titled, “Accelerated Longitudinal Weight Gain Among Infants WithCOVID-19 Exposure.” Also, get a sneak peak at an episode of our members-only podcastwhich looks at a study inabout the glycemic gap in hospitalized patients with COVID. Show notes are available at https://www.endocrine.org/podcast/enp76-infants-and-in-utero-exposure-to-covid — for helpful links or to hear more podcast episodes, visit https://www.endocrine.org/podcast

From ENDO 2023, host Aaron Lohr talks with Jayalakshmi Udayasankar, MD, from the Palo Alto Medical Foundation, about her team’s research presented at the meeting, titled, “Tingling Over Cheek: An Atypical Presentation of Invasive Fungal Sinusitis in an Ambulatory Patient With Type 2 Diabetes.” Show notes are available at https://www.endocrine.org/podcast/enp75-a-case-study-on-fungal-sinusitis-in-t2d — for helpful links or to hear more podcast episodes, visit https://www.endocrine.org/podcast

In another dispatch from ENDO 2023, host Aaron Lohr talks with Max Petersen, MD, PhD, from Washington University in St. Louis, about his team’s research presented at the meeting. Their presentation was titled, “Cellular Insights Into Metabolically Healthy and Unhealthy Obesity.” Show notes are available at https://www.endocrine.org/podcast/enp74-healthy-and-unhealthy-obesity — for helpful links or to hear more podcast episodes, visit https://www.endocrine.org/podcast

Host Aaron Lohr talks with two researchers at ENDO 2023, Kyle Horlen, DVM, and Joshua Myers, both from Rani Therapeutics, about two presentations they made about an oral treatment of teriparatide for the treatment of osteoporosis. The two presentations are titled, “Pharmacokinetics (PK) and Pharmacodynamics (PD) of the Parathyroid Hormone Analog PTH (1-34) (Teriparatide) Delivered via an Orally Administered Robotic Pill (RT-102),” and “An Orally Administered Robotic Pill (RP) Reliably And Safely Delivers the Human Parathyroid Hormone Analog hPTH(1-34) (Teriparatide) With High Bioavailability in Healthy Human Volunteers: A Phase 1 Study.” Show notes are available at https://www.endocrine.org/podcast/enp73-a-robotic-teriparatide-pill-to-treat-osteoporosis — for helpful links or to hear more podcast episodes, visit https://www.endocrine.org/podcast

In another interview from ENDO 2023, host Aaron Lohr talks with Silvana Duran Ortiz, Ph.D., a postdoctoral research fellow at Ohio University, about her team’s research presented at the meeting. Their presentation was titled, “Disruption of GHR in ‘Middle Aged’ Mice Enhances Insulin Sensitivity and Extends Male Lifespan.” Show notes are available at https://www.endocrine.org/podcast/enp72-ghr-insulin-and-life-span — for helpful links or to hear more podcast episodes, visit https://www.endocrine.org/podcast

Host Aaron Lohr went to Chicago in June to interview researchers presenting at the Endocrine Society’s annual meeting, ENDO 2023. Here he talks with Julie Hens, PhD, from Yale University about her team’s research, titled “Protective Effects of Lactation on Maternal Metabolism.” After that interview, listen to a sneak peek of our other, members-only podcast,, an episode from November 2022 about changes in glucose throughout the menstrual cycle in type 1 diabetes. Show notes are available at https://www.endocrine.org/podcast/enp71-lactation-and-maternal-metabolism — for helpful links or to hear more podcast episodes, visit https://www.endocrine.org/podcast

Whether we like it or not, we’re all getting older. What do we know about how aging impacts our endocrine system? What don’t we know? That’s what we’re here to talk about today, as we look at the new scientific statement from the Endocrine Society titled, “Hormones and Aging: An Endocrine Society Scientific Statement.” Host Aaron Lohr talks with one of the statement’s authors, Anne Cappola, MD, a professor of medicine at the University of Pennsylvania and founding director of Penn Medical Communication Research Institute. Show notes are available at https://www.endocrine.org/podcast/enp70-hormones-and-aging — for helpful links or to hear more podcast episodes, visit https://www.endocrine.org/podcast

In this episode, we hear about biosimilar insulin: its safety, efficacy, what sets it apart from biologic insulin, and when it should be considered for use. Host Aaron Lohr talks with Irl Hirsch, MD, professor of medicine at the University of Washington Medicine Diabetes Institute. This episode is made possible through an unrestricted, educational grant from Viatris. Show notes are available at https://www.endocrine.org/podcast/enp69-biosimilar-insulin — for helpful links or to hear more podcast episodes, visit https://www.endocrine.org/podcast

Recently the Endocrine Society published a new clinical practice guideline entitled, “Treatment of Hypercalcemia of Malignancy in Adults: An Endocrine Society Clinical Practice Guideline.” What exactly is hypercalcemia of malignancy? What are its symptoms? How is it treated? And what do the guidelines recommend? To help answer these questions, host Aaron Lohr talks with Ghada El-Hajj Fuleihan, MD, MPH, professor of medicine at the American University in Beirut in Lebanon. She is the chair of the Society working group that developed this guideline. Show notes are available at https://www.endocrine.org/podcast/enp68-hypercalcemia-of-malignancy — for helpful links or to hear more podcast episodes, visit https://www.endocrine.org/podcast

In this episode, host Aaron Lohr discusses screening, diagnosis, and current and emerging treatment options for the long-term management of growth hormone deficiency in pediatric and adult patients with Dr. Mark E. Molitch, MD, Professor Emeritus of Medicine, Northwestern University Feinberg School of Medicine. In addition, Dr. Molitch gives listeners a four-question quiz at the end. Remember to pause in between the question and answer! This episode is certified for up to 0.5 American Medical Association Physician’s Recognition Award (AMA PRA) Category 1 credits and American Board of Internal Medicine Maintenance of Certification (ABIM MOC) points. This episode is made possible by an unrestricted, educational grant from Novo Nordisk. Show notes are available at https://www.endocrine.org/podcast/enp67-growth-hormone-deficiency — for helpful links, including to the AMA PRA exam, or to hear more podcast episodes, visit https://www.endocrine.org/podcast

The Endocrine Society made news recently by launching a new, online-only, open-access journal called, which is dedicated to clinical cases in endocrinology. What can we learn from case studies, and what does this journal have to offer? To answer those questions, host Aaron Lohr talks withEditor-in-Chief William F. Young Jr., MD, the Tyson Family Endocrinology Clinical Professor and professor of medicine in the Mayo Clinic College of Medicine at Mayo Clinic in Rochester, Minn. Show notes are available at https://www.endocrine.org/podcast/enp66-new-endocrine-society-journal-jcem-case-reports — for more information, including helpful links and other episodes, visit our website at https://www.endocrine.org/podcast

In this episode, host Aaron Lohr looks back at the Endocrine Society’s Type 1 Diabetes Fellows Conference, which occurred last year, with two conference presenters talking about developmental challenges in type 1 diabetes, including psychological and social, across the lifespan. Our guests are Linda Siminerio, PhD, professor of medicine at University of Pittsburgh and executive director of the university’s Diabetes Institute, and Jill Weissberg-Benchell, PhD, professor of psychiatry and behavioral sciences at Northwestern University. Dr. Siminerio’s presentation was titled, “Identifying and Confronting Challenging Transitions.” Dr. Weissberg-Benchell’s presentation was titled, “Developmental Perspectives in the Psychosocial Aspects of Diabetes.” Thanks to the conference’s supporters who have made this episode possible through unrestricted, educational grants: Abbott Laboratories, Dexcom, Insulet, Lilly, Medtronic, Novo Nordisk, PreventionBio, and Tandem Diabetes Care. Editor’s note: this interview was recorded in 2022. Show notes are available at https://www.endocrine.org/podcast/enp65-type-1-diabetes-and-challenges-across-the-lifespan — for more information, including helpful links and other episodes, visit our website at https://www.endocrine.org/podcast

In this episode, Aaron talks with Travis Goettemoeller, MD, internal medicine resident at Cleveland Clinic, about an abstract he and a colleague presented at ENDO 2022 about the bone mineral density testing of men for hypogonadism. The abstract is titled, “Lack of Bone Mineral Density Testing in Men with Hypogonadism: A Clinical Conundrum.” Show notes are available at https://www.endocrine.org/podcast/enp64-more-testing-needed-for-men-with-hypogonadism — for more information, including helpful links and other episodes, visit our website at https://www.endocrine.org/podcast

We look at Vosoritide, a promising, potential treatment for children with genetic short stature who do not have chondrodysplasia. Host Aaron Lohr talks with Andrew Dauber, MD, division chief of endocrinology at Children’s National Hospital. Dr. Dauber and colleagues presented about Vosoritide at ENDO 2022. Their abstract is titled, “A Prospective Clinical Trial of Vosoritide in Selected Genetic Causes of Short Stature.” Show notes are available at https://www.endocrine.org/podcast/enp63-vosoritide-and-children-with-genetic-short-stature — for more information, including helpful links and other episodes, visit our website at https://www.endocrine.org/podcast

Endocrine-disrupting chemicals are pretty much everywhere, and all of us have some level of exposure. Today we will talk about research presented at ENDO 2022 on a group of EDCs called parabens. The title of that abstract is “Parabens Promote Pro-Tumorigenic Effects in Luminal Breast Cancer Cell Lines With Diverse Genetic Ancestry.” Host Aaron Lohr talks with one of the authors of that study, Lindsey Treviño, PhD, assistant professor at City of Hope National Medical Center. They talk not just about the effects of parabens as an EDC, but also about racial and ethnic disparities in risk and mortality, as well as research, and how Dr. Treviño and colleagues address these disparities. Show notes are available at https://www.endocrine.org/podcast/enp62-parabens-as-an-edc-and-addressing-disparities-in-risk-and-research — for more information, including helpful links and other episodes, visit our website at https://www.endocrine.org/podcast